Kuur Therapeutics is committed to transforming the lives of patients with cancer & is leading the development cell therapies.
Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies.Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 25, 2014 | Series B | £50M | 1 | — | — | Detail |
Jul 23, 2012 | Series Unknown | £17M | 1 | — | — | Detail |